Glucose‑Lowering Therapy in Patients with End‑Stage Renal Disease and Type 2 Diabetes
Contraindicated First‑Line Agents
- KDIGO 2022 recommends stopping metformin when eGFR < 30 mL/min/1.73 m² and advises against initiating metformin at this renal function because of the risk of lactic acidosis. 1
- SGLT2 inhibitors (e.g., dapagliflozin) must not be started in patients who are already on dialysis; the contraindication is absolute despite their cardiovascular benefits in earlier CKD stages. 2
- The glucose‑lowering effect of SGLT2 inhibitors is essentially lost when eGFR < 45 mL/min/1.73 m². 2
Recommended Therapy in ESRD
- Insulin is the only glucose‑lowering medication that is both safe and cost‑effective across all levels of kidney function, including dialysis, because other agents are contraindicated. 1
- Insulin dose should be reduced by 25–50 % when patients transition from pre‑dialysis to dialysis to prevent severe hypoglycemia. 2
- Close hypoglycemia monitoring is essential in dialysis patients, as insulin requirements frequently decline. 2
Alternative Oral Options
- Linagliptin is the only DPP‑4 inhibitor that does not require dose adjustment in ESRD and can be used safely in dialysis patients. 1
- Other DPP‑4 inhibitors (sitagliptin, saxagliptin, alogliptin) require significant dose reductions in ESRD. 2
- Sulfonylureas may be used in ESRD but carry a high hypoglycemia risk due to accumulation of active metabolites; glipizide is preferred over glyburide, which has renally cleared metabolites. 1
Safety and Monitoring
- Continuing metformin in ESRD is contraindicated because the risk of fatal lactic acidosis outweighs any benefit. 1
- A1c should be measured every 3 months with a relaxed target of 7.5–8.5 % in older patients with ESRD. 1
- Glyburide should be avoided in ESRD because its renally cleared metabolites cause prolonged hypoglycemia. 2